Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
69.8M
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
56.1M
-
Shares change
-
+3.8M
-
Total reported value, excl. options
-
$1.4B
-
Value change
-
+$97.8M
-
Put/Call ratio
-
0.33
-
Number of buys
-
62
-
Number of sells
-
-52
-
Price
-
$24.96
Significant Holders of Kymera Therapeutics, Inc. - Common Stock (KYMR) as of Q4 2022
145 filings reported holding KYMR - Kymera Therapeutics, Inc. - Common Stock as of Q4 2022.
Kymera Therapeutics, Inc. - Common Stock (KYMR) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.1M shares
of 69.8M outstanding shares and own 80.4% of the company stock.
Largest 10 shareholders include Atlas Venture Life Science Advisors, LLC (5.98M shares), BVF INC/IL (4.69M shares), WELLINGTON MANAGEMENT GROUP LLP (4.59M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.38M shares), Avoro Capital Advisors LLC (3.85M shares), VANGUARD GROUP INC (3.66M shares), BlackRock Inc. (3.33M shares), BAKER BROS. ADVISORS LP (2.88M shares), STATE STREET CORP (2.85M shares), and Redmile Group, LLC (2.67M shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.